SIBN Stock — Si-Bone Inc

Si-Bone Inc (SIBN)

Updated October 16, 2026.

SIBN is a Stock. Total return is -1.9% over the past 8 years, 208.7 points behind SPY at 206.8%.

SI-BONE, Inc. is a medical device company that develops titanium implants and instruments for spinal fusion and sacroiliac joint stabilization procedures, with a portfolio including the IFUSE family of implants designed for bone fusion and fixation. The company markets its products through a direct sales force and third-party distributors. SI-BONE does not currently distribute dividends to shareholders, making it oriented toward growth-focused investors rather than those seeking current income.

SIBN performance versus SPY

Price and return data through 2026-10-16.

Total return is -1.9% over the past 8 years, 208.7 points behind SPY at 206.8%. Over the past year its total return — price change plus distributions reinvested — is 30.3%. Its deepest 1-year drawdown was 45.7%.

SIBN key facts

Asset type

Stock

Asset class

Equity

Inception date

10/17/2018

Distribution frequency

None

Last close

$19.68 (as of 2026-10-16)

Market cap

$872,793,889

Average volume

1165644.0

Beta

0.705

Payout ratio

0.0%

EPS

$-0.33

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

SIBN risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 45.7%.

Who may consider SIBN — and who may not

It is a weaker fit for investors who need monthly cash flow (SIBN does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on SIBN

• All tickers starting with S

Tagged: Healthcare.

Frequently asked questions